Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 39 of 1,261
  1. US 12318454

    Bicyclic peptide ligands specific for MT1-MMP

    BicycleRD Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  2. US 12318418

    Modified adenoviruses

    University College Cardiff Consultants Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  3. US 12318397

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  4. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Karyopharm Therapeutics Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  5. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  6. US 12318356

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  7. US 12318376

    Compositions of a polyorthoester and an aprotic solvent

    Heron Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  8. US 12318364

    Isoflavonoid compositions and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  9. US 12318426

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  10. US 12318401

    Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

    The Regents of the University of California · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  11. US 12318413

    Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

    The Board of Regents of the University of Texas System · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  12. US 12317874

    Method of using a genetically modified mouse that expresses human albumin

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  13. US 12318487

    Solid tablet dosage form of ridinilazole

    SUMMIT (OXFORD) LIMITED · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  14. US 12318457

    Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  15. US 12319724

    IL2 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  16. US 12318375

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  17. US 12319703

    Macrocyclic fused pyrazoles as Mcl-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  18. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  19. US 12318362

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  20. US 12319940

    Methods for purification of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  21. WO 2025111409

    COMPOSÉS HÉTÉROCYCLIQUES DE FORMULE (I) DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'AMYOTROPHIE SPINALE PAR MODULATION DE L'ÉPISSAGE DE SMN2

    BIOGEN MA INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted
  22. WO 2025108443

    COMPOSÉS HÉTÉROCYCLIQUES ET COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT CORRESPONDANTES

    BEIGENE SWITZERLAND GMBH [CH] · Granted May 30, 2025 · Expires May 25, 2045

    granted
  23. WO 2025111258

    COMPOSITIONS DE SÉROTYPE A DE NEUROTOXINE DE CLOSTRIDIUM BOTULINUM ET PROCÉDÉS DE FILTRATION AMÉLIORÉS

    ABBVIE INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted
  24. WO 2025111408

    COMPOSÉS POUR LE TRAITEMENT DE L'AMYOTROPHIE SPINALE ET DE LA MALADIE DE HUNTINGTON

    BIOGEN MA INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.